STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
AI Summary
The FDA's green light for Vera Therapeutics' Trutakna marks a significant breakthrough for patients suffering from IgA nephropathy, a challenging kidney disease. This approval underscores the potential of innovative therapies to address rare but serious medical conditions. Meanwhile, the U.K. has secured a favorable pricing deal for Enhertu, a cancer treatment, highlighting efforts to balance cost and access in healthcare. These developments signal progress in both pharmaceutical innovation and healthcare policy.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.